title: [Nosocomial infection due to Trichosporon asahii: clinical revision of 22 cases].
abstract: Twenty two cases of nosocomial infection caused by Trichosporon asahii, detected during a period of six years (1999-2005) is described. The patients were predominantly males with an average age of 47.3 years-old. The predominant diseases in the study group were respiratory insufficiency, cancer, diabetes, chronic renal insufficiency, cirrhosis and AIDS. The main predisposing conditions were antibiotic therapy, mechanical ventilation, urethral catheterization, catheter, corticoids, transplant, immunosuppressive therapy, chemotherapy, granulocytopenia, surgical procedures and continuous ambulatory peritoneal dialysis. The most used antifungal drugs were fluconazole and amphotericin B. In some cases several antifungals were administered. Five patients did not receive antifungal treatment, and one patient received granulocyte colony stimulating factor (G-CSF). Nine patients showed clinical improvement, nine died and the progress of four patients is unknown. T. asahii is an emergent pathogen in patients with immunodeficiency and its presence in these type hosts can not be considered colonization, as there is an important risk of invasive infection. So, in susceptible patients to develop trichosporonosis it is advisable to take into consideration this disease especially in intensive clinical care units.
authors.affiliation: Laboratório SANI, Passo Fundo, Brasil.
authors.forename: Gustavo da Silva
authors.initials: Gda S
authors.lastname: Rodrigues
authors.forename: Rodrigo Rosa Ubatuba
authors.initials: RR
authors.lastname: de Faria
authors.forename: Lucina Silva
authors.initials: LS
authors.lastname: Guazzelli
authors.forename: Flávio de Mattos
authors.initials: Fde M
authors.lastname: Oliveira
authors.forename: Luiz Carlos
authors.initials: LC
authors.lastname: Severo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000380:Agranulocytosis / Q000188:drug therapy / Q000209:etiology; D000935:Antifungal Agents / Q000627:therapeutic use; D001826:Body Fluids / Q000382:microbiology; D001938:Brazil / Q000453:epidemiology; D002648:Child; D021821:Communicable Diseases, Emerging / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D003428:Cross Infection / Q000382:microbiology*; D005260:Female; D016469:Fungemia / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D017052:Hospital Mortality; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D009894:Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D012189:Retrospective Studies; D016896:Treatment Outcome; D014250:Trichosporon / Q000302:isolation & purification*; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology
chemical_list: D000935:Antifungal Agents; D016179:Granulocyte Colony-Stimulating Factor